Join the Oncology Voice Network. Join for Free
The OVERLOOKED KOL
Advanced Practice Providers Medical Science Liaison Key Opinion Leaders Physician Assistants Nurse Practitioners

The OVERLOOKED KOL


Share This Article


Summary

In this episode, Tom Caravela hosts Leticia Price and Dawn O'Reilly to discuss the critical role of Advanced Practice Providers (APPs) in the medical field. They explore the educational backgrounds and capabilities of APPs, emphasizing their often underutilized potential as Key Opinion Leaders (KOLs). Strategies for effectively identifying and engaging APPs are shared, along with advice for Physician Assistants (PAs) and Nurse Practitioners (NPs) transitioning to Medical Science Liaison (MSL) roles. The conversation highlights the importance of networking, resource utilization, and effective time management. The episode concludes with insights into the value of APPs in medical progress and territory planning.

My guests this week are Medical Science Liaisons, Dawn O'Reilly and Letitia Price, who discuss the benefits of Medical Science Liaisons engaging with Advanced Practice Providers.

Learn more about…

πŸ‘‰ What are APPs
πŸ‘‰ Why should MSLs be calling on APPs
πŸ‘‰ How can an NP or PA transition to industry
πŸ‘‰ Why are NPs and PA’s often overlooked
πŸ‘‰ How can MSLs find success in their territory

Click for Source
Advanced Practice Providers, Medical Science Liaison, Key Opinion Leaders, Physician Assistants, Nurse Practitioners

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies β€” and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN